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https://doi.org/10.1016/j.stemcr.2018.08.016SUMMARYTyrosine kinase inhibitors (TKi) are effective against chronic myeloid leukemia (CML), but their inefficacy on leukemia stem cells
(LSCs) may lead to relapse. To identify new druggable targets alternative to BCR/ABL, we investigated the role of the MEK5/ERK5
pathway in LSC maintenance in low oxygen, a feature of bone marrow stem cell niches. We found that MEK5/ERK5 pathway
inhibition reduced the growth of CML patient-derived cells and cell lines in vitro and the number of leukemic cells in vivo. Treat-
ment in vitro of primary CML cells with MEK5/ERK5 inhibitors, but not TKi, strikingly reduced culture repopulation ability
(CRA), serial colony formation ability, long-term culture-initiating cells (LTC-ICs), and CD26-expressing cells. Importantly,
MEK5/ERK5 inhibition was effective on CML cells regardless of the presence or absence of imatinib, and did not reduce CRA
or LTC-ICs of normal CD34+ cells. Thus, targeting MEK/ERK5 may represent an innovative therapeutic approach to suppress
CML progenitor/stem cells.INTRODUCTION
The pathogenesis of chronic myeloid leukemia (CML) is
centered on the BCR/ABL fusion gene and the subsequent
expression of the constitutively active BCR/ABL tyrosine
kinase (Rowley, 1973). The introduction of imatinib, the
prototype of tyrosine kinase inhibitors (TKi) capable to
target BCR/ABL, opened a new era in CML treatment, al-
lowing up to 90% of chronic-phase patients to achieve
deep molecular response and prolonged survival (Druker
et al., 2006). However, TKi do not show the same efficacy
in the treatment of patients in accelerated phase or blast
crisis. In addition, following discontinuation of TKi,
most patients relapse (Mahon et al., 2010), likely due to
the insensitivity to TKi of leukemia stem cells (LSCs)
(Graham et al., 2002; Giuntoli et al., 2006, 2011), the
cell subset that sustains minimal residual disease (Ghiaur
et al., 2012). Thus, the identification of druggable targets
different from BCR/ABL is a crucial goal to aim at CML
eradication.
The extracellular signal-regulated kinase 5 ([ERK5],
also referred to as big mitogen-activated kinase 1
[BMK1]) belongs to the mitogen-activated protein kinase
family (Lee et al., 1995), and is emerging as a promising
target for cancer treatment, also thanks to the availability
of small-molecule inhibitors of ERK5 or its upstream acti-
vator MEK5 (Yang et al., 2010; Tatake et al., 2008; Simo˜esStem
This is an open access article under the Cet al., 2016; Lin et al., 2016). Cytokines, growth factors
(Rovida et al., 2008), and stress factors are upstream acti-
vators of MEK5, which activates ERK5 through phos-
phorylation at Thr218/Tyr220 (Drew et al., 2012; Nithia-
nandarajah-Jones et al., 2012). The MEK5/ERK5 pathway
is involved in the pathogenesis of different types of can-
cer (McCracken et al., 2008; Esparis-Ogando et al., 2002;
Rovida et al., 2015; Carvajal-Vergara et al., 2005; Tusa
et al., 2018), and ERK5 has been reported to contribute
to the oncogenic potential of BCR/ABL (Buschbeck
et al., 2005).
Low oxygen is a critical environmental condition
ensuring the maintenance of hematopoietic stem cells
(HSCs) (Cipolleschi et al., 1993; Danet et al., 2003; Parmar
et al., 2007; Eliasson and Jonsson, 2010; Ivanovic et al.,
2002), 0.1% O2 being a physiological occurrence in bone
marrow (BM) (Chow et al., 2001) that allows HSC cycling
(Hermitte et al., 2006; Guitart et al., 2011). Incubation at
0.1% O2 suppressed BCR/ABL protein and allowed to
select, from the BCR/ABL-dependent CML cell bulk, CML
cells which can survive and cycle independently of BCR/
ABL signaling. These cells retain progenitor/stem cell po-
tential and result refractory to TKi (Giuntoli et al., 2006,
2007, 2011; Cheloni et al., 2017).
In this study, we investigated the role of the ERK5
pathway in the maintenance of CML LSCs in view of its
possible therapeutic inhibition.Cell Reports j Vol. 11 j 1–15 j October 9, 2018 j ª 2018 The Author(s). 1
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. ERK5 Expression and Effects of ERK5 Pathway Inhibition in CML Cells
(A and B) ERK5 expression in human CML cell lines and primary cells. Immunoblotting of total cell lysates of routinely cultured (A) CML cell
lines or (B) BMMCs from CML patients. (A) Slower-migrating phosphorylated form of ERK5 (arrow). GAPDH or tubulin are loading controls.
Representative images from three (A) or two (B) independent experiments.
(C–E) Effects of MEK5/ERK5 inhibitors on KCL22 and K562 cell number and cell-cycle phase distribution in low oxygen. Cells were incubated
in 0.1% O2 and treated with DMSO (Vehicle) or the indicated inhibitors from time 0 to the indicated times. (C) Viable cell count; values are
means ± SD of data from three independent experiments; *p < 0.05; **p < 0.01 versus vehicle at the same time point. (D) Cell-cycle phase
distribution; representative plots from three independent experiments, averaged (means ± SEM) in the table; *p < 0.05, **p < 0.01 versus
vehicle. (E) Immunoblotting of total cell lysates of CML cell lines; tubulin is a loading control; representative images from four inde-
pendent experiments.
(legend continued on next page)
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The ERK5 Pathway Is Active and Required for Optimal
Growth in CML Cells
The expression of ERK5 protein in myeloid leukemia cell
lines, including K562 CML cells, has been reported previ-
ously (Buschbeck et al., 2005; Wang et al., 2014). We
show here that in the K562, KCL22, and LAMA84 CML
cell lines ERK5 was phosphorylated at the activation loop
residues Thr218/Tyr220, so that an ERK5 band with
reduced electrophoretic mobility was detectable (Fig-
ure 1A). The constitutive activity of ERK5 was confirmed
by in vitro kinase assay (Figures S1A and S1B) in KCL22
and K562 cells, widely used as CML models and therefore
chosen for further experiments in vitro. Importantly,
ERK5 was expressed and phosphorylated at Thr218/
Tyr220 in bone marrow mononuclear cells (BMMCs)
from CML patients (Figure 1B).
We then evaluated the role of ERK5 in CML cell growth,
using the ERK5 inhibitor XMD8-92 (Yang et al., 2010) and
the MEK5 inhibitor BIX02189 (Tatake et al., 2008). Either
drug reduced the number of viable cells in culture in a con-
centration-dependent manner (Figures S1C and S1D). On
the basis of previous studies (Rovida et al., 2015; Sureban
et al., 2014; Kim et al., 2013) and in order to reduce possible
off-target effects, we performed all subsequent experiments
using an XMD8-92 and BIX02189 concentration (10 mM)
lower than the half maximal inhibitory concentration
(IC50) values determined in KCL22 and K562 cells incu-
bated in normoxia or low oxygen (0.1% O2; Figure S1E).
This inhibitor concentration was able to suppress the
constitutive ERK5 kinase activity (Figures S1A and S1B)
and to reduce significantly KCL22 and K562 cell growth
(Figure S1F). This reduction was lower than that induced
by imatinib (Figure S1F) used at a concentration (1 mM)
around 2-fold the IC50 reported previously (Cheloni et al.,
2017; Rix et al., 2007; Cassuto et al., 2012). The lack of ef-
fect of 10 mM XMD8-92 on the proliferation of K562 cells
where ERK5 expression had been suppressed by small
hairpin RNA (shRNA) led to exclude possible off-target ef-
fects of XMD8-92 at this concentration (Figures S1G and
S1H) (Lin et al., 2016).
Subsequent experiments directed to study the role of the
ERK5 pathway in the maintenance of CML progenitor/
stem cell potential were performed incubating cells in
low oxygen. In low oxygen, similarly to that observed in
normoxia (Figure S1F), a 3-day treatment with XMD8-92
or BIX02189 reduced the number of viable KCL22 and(F and G) Effects of MEK5/ERK5 inhibitors on primary CML cells. Patie
(Vehicle), 10 mM XMD8-92 (XMD), or 10 mM BIX02189 (BIX) from time
cells (n = 3); *p < 0.05 versus vehicle. (G) Data are means ± SD of data
drug- and vehicle-treated samples were not statistically significant.K562 cells (Figure 1C). The effect of XMD8-92 or
BIX02189 in reducing cell number was apparently due to
a block of cell cycle in G0/G1 phase (Figure 1D) rather
than to the induction of apoptosis. Indeed, while imatinib,
as expected, induced apoptosis, XMD8-92 or BIX02189 did
not (Figures S2A and S2B). The G0/G1 block was consistent
with the increased expression of p27 (Figure 1E), a critical
negative regulator of cell-cycle progression. We obtained
similar results incubating cells in normoxia (Figures S2C–
S2G). With respect to primary CML BMMCs, XMD8-92
and BIX02189 induced apoptosis significantly (Figure 1F),
while showing appreciable but not significant G0/G1 cell
accumulation at the expense of the S phase (Figure 1G).
Inhibition of the ERK5 Pathway Reduces Progenitor
Cell Potential of CML Cell Lines in Low Oxygen
To identify a druggable target to achieve LSC suppression,
we tested the effects ofMEK5/ERK5 inhibitors on themain-
tenance of CML progenitor cell potential using CML cell
lines as a first approach (Figure 2). KCL22 and K562 cells
were treated with XMD8-92 or BIX02189 from time 0 of in-
cubation in low oxygen (LC1) and transferred on day 7 to
drug-free cultures (LC2) incubated in normoxia (Figure 2A),
to evaluate the progenitor cell potential of LC1 cells by the
culture repopulation ability (CRA) assay (Giuntoli et al.,
2006, 2011). ERK5 pathway inhibition markedly reduced
(BIX02189) or suppressed (XMD8-92) the progenitor cell
potential of KCL22 and K562 cells, while imatinib showed
negligible effects as reported previously (Giuntoli et al.,
2006, 2011). Conversely, the appropriateness of ERK5 tar-
geting inCML cells incubated in low oxygenwas supported
by the fact that ERK5 protein was maintained, although
partially reduced with respect to time 0 (Figure S3A). The
reduction of ERK5 protein level following BCR/ABL protein
suppression is consistent with a previous report showing
that ERK5 protein level depends on BCR/ABL only in part
(Buschbeck et al., 2005). This partial dependence was
confirmed by showing that ERK5 expression level in low
oxygen remained relatively high upon imatinib treatment
despite BCR/ABL inhibition, which was witnessed by the
markedly reduced phosphorylation of the BCR/ABL target
CRKL (Figure S3B).
To confirm that the above-described effects of drugs were
due to ERK5 pathway inhibition, we performed ERK5
knockdown using shRNA. Genetic inhibition of ERK5 (Fig-
ure 2B, inset) halved the number of viable K562 cells in low
oxygen (Figure 2B) and suppressed CRA (Figure 2C). Taken
together, these results indicated that the ERK5 pathwaywasnt-derived cells were incubated in normoxia and treated with DMSO
0 to day 3. (F) Data are means ± SD of the percentages of apoptotic
(n = 3) showing cell-cycle phase distribution. Differences between
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Figure 2. Effects of ERK5 Pathway Inhibi-
tion on the Progenitor Cell Potential of
CML Cell Lines
(A) Effects of MEK5/ERK5 inhibitors on
CRA. Kinetics of repopulation of drug-
free normoxic secondary cultures (LC2)
established with KCL22 or K562 cells
rescued from primary cultures (LC1) incu-
bated in 0.1% O2 and treated for 7 days
with DMSO (Vehicle) or the indicated in-
hibitors. Values are means ± SD of three
independent experiments. Differences be-
tween drug- and vehicle-treated cultures
were significant (p % 0.01) from day 21
(KCL22) or day 17 (K562) on for BIX02189,
and from day 14 (KCL22) or day 10 (K562)
on for XMD8-92.
(B and C) Effects of ERK5 genetic inhibition
in K562 cells on cell number and CRA.
(B) Cells transduced with (inset) non-tar-
geting control (shNT) or two different ERK5-
targeting shRNA (shERK5-1, shERK5-2)
were incubated in 0.1% O2 and viable cells
counted at the indicated times of LC1.
*p % 0.05 versus shNT at the same time
point. (C) LC2 repopulation by cells from day 7 LC1 shown in (B). Values are means ± SD of three independent experiments. Differences
between shERK5-1 or shERK5-2 with respect to the shNT control were significant (p < 0.05) from day 24 on.
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of CML cell lines.
Pharmacological Inhibition of the ERK5 Pathway
Reduces the Number and Colony Formation Ability of
Primary CMLCells as well as the Number of CMLCells
In Vivo
We next evaluated the effects of MEK5/ERK5 inhibitors on
primary CML cells. The effects of ERK5 (ten patients) or
MEK5 (four patients) inhibition on the number of viable
BMMCs in low oxygen is shown in Figures 3A and S4A.
XMD8-92 and BIX02189 determined a reduction of viable
BMMCs ranging from negligible (nos. 4, 9, 17, and 25) to
marked (nos. 10, 16, 28, and 29) (Figure S4A). When the
data obtained for the single patients were pooled together,
it emerged that, in keeping with that observed for CML cell
lines, the detrimental effect of XMD8-92 or BIX02189 on
the overall cell viability was significant, although not
exceeding that of TKi (Figure 3A). Furthermore, XMD8-92
and BIX02189, similarly to TKi, robustly reduced the col-
ony formation ability (CFA) of BMMCs from CML patients
(Figure 3B). It is worth noting that in the same experiments
3 mM XMD8-92 was also effective.
The effects of pharmacological inhibition of ERK5 were
also tested in vivo using mice transplanted with BCR/ABL-
transduced cells (Li et al., 1999; Peng and Li, 2010). CML
mice were treated twice daily with XMD8-92 (50 mg/kg)4 Stem Cell Reports j Vol. 11 j 1–15 j October 9, 2018or placebo for 7 days starting 1 week after transplantation.
Fluorescence-activated cell sorter analysis showed that the
numbers of GFP+ (BCR/ABL-expressing; Figures 3C and
S4B), but not GFP (BCR/ABL-negative; Figure 3C and
data not shown) andmyeloid (Gr-1+) cells decreased signif-
icantly in BM and peripheral blood (PB) of XMD8-92-
treated mice compared with the placebo group. Viable
cell numbers in BM (Figure 3C) and PB (not shown) of
XMD8-92-treated mice did not decrease significantly
when comparedwith the placebo-treated group, in keeping
with the lack of a general toxicity of XMD8-92 (Yang et al.,
2010; Rovida et al., 2015; Carvajal-Vergara et al., 2005).
We then tested the effects of ERK5 pathway inhibition on
CD34+ BMMCs fromCML patients. A 2-day treatment with
XMD8-92 or BIX02189 in low oxygen reduced the number
of viable CD34+ cells markedly and similarly to imatinib.
Importantly, XMD8-92 or BIX02189 did not affect the
viability of normal CD34+ peripheral blood mononuclear
cells (PBMCs) incubated in low oxygen (Figure 3D). XMD8-
92 and BIX02189 decreased CFA of CD34+ CML cells in a
concentration-dependent manner (Figure 3E). Importantly,
1 and 3 mM concentrations of XMD8-92 and BIX02189
were effective on cells from CML patients, but not from
healthy donors (Figures 3E, S4C, and S4D). Furthermore,
XMD8-92 and BIX02189 dose-dependently reduced CFA of
CFU-GEMM (colony-forming unit granulocyte, erythroid,
monocyte, macrophage) and BFU-E (burst-forming unit
Figure 3. Effects of Pharmacological Inhibition of the ERK5 Pathway In Vivo and on Primary CML and Normal CD34+ Cells
(A) Effects of MEK5/ERK5 inhibitors on the number of viable primary CML cells. CML BMMCs were incubated at 0.1% O2 and treated with
DMSO (Vehicle) or the indicated inhibitors (XMD, XMD8-92; BIX, BIX02189; IM, imatinib; DAS, dasatinib) and viable cells counted at day 3.
Values are means ± SD. See Figure S4A for single patient data. The number of patients for each group is indicated (vehicle group: n = 10).
*p% 0.05; **p% 0.01.
(B) Effects of MEK5/ERK5 inhibitors on the CFA of primary CML cells. CML BMMCs were treated with DMSO (Vehicle) or inhibitors from time
0 and colonies scored after 7 days. Colony formation efficiency (CFE) values are means ± SD of data from single experiments performed in
duplicate; *p% 0.05; **p% 0.01.
(C) Effects of XMD8-92 in vivo. CML mice (mice/group: n = 6) were treated twice daily with XMD8-92 (50 mg/kg) or placebo and euthanized
after 1 additional day. Number of GFP+ (leukemic) or GFP (non-leukemic) myeloid (Gr-1+) BM cells; data are means ± SD (left graph).
Total number of viable BM cells; data are means ± SD (right graph). *p < 0.05; ns, not significant.
(D) Effects of MEK5/ERK5 inhibitors on the number of viable primary CML and normal CD34+ cells. CD34+-enriched CML BMMCs or healthy
donor PBMCs were treated with DMSO (Vehicle) or inhibitors at the indicated concentrations and incubated in 0.1% O2 and viable cells
counted at day 2. Values are means ± SD of data normalized for the respective vehicle-treated control. The number of patients/healthy
donors is indicated; **p% 0.01; ***p% 0.001; ns, not significant.
(E) Effects of MEK5/ERK5 inhibitors on CFA of primary CML or normal CD34+ cells. CD34+-enriched CML BMMCs or healthy donor PBMCs were
treated with DMSO (Vehicle) or inhibitors at the indicated concentrations from time 0 and colonies scored after 7 days. CFE values are
(legend continued on next page)
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potential, from CML patients (Figure 3F). Effects on CFU-
GM (colony-forming unit granulocyte macrophage) were
observed only with the highest concentration of either
drug. These effects matched those of imatinib. By contrast,
XMD8-92 or BIX02189 showed no effect on CFA of CFU-
GEMMfromnormalCD34+PBMCs,withappreciable effects
on BFU-E and, at the highest doses, on CFU-GM (Figure 3G).
Figure3Hshows thatXMD8-92andBIX02189prevented the
decrease of CD11b+ cells occurring along a 3-day incubation
in culture with respect to time 0, confirming that ERK5
pathway inhibitors are more effective on primitive rather
than differentiated cells. These results are in keeping with a
previous report indicating that ERK5 pathway inhibition in-
creases the number of CD11b-positive cells in myeloid cell
lines (Wangetal., 2014).Takentogether, thesedata indicated
that pharmacological inhibition ofMEK5/ERK5 reduced the
overall cell number and CFA of primary CML cells, affecting
in particular the more immature progenitors, and the num-
ber of CML cells in vivo.
Pharmacological Inhibition of the ERK5 Pathway
Reduces Progenitor and StemCell Potential of Primary
CML Cells
We first tested the effects of MEK5/ERK5 inhibitors on the
maintenance of progenitor cell potential of primary CML
cells. Figure 4A shows that XMD8-92 suppressed the CRA
of primary cells from eight out of nine (except no. 24)
CML patients, including one BC patient (no. 4), matching
what shown in Figure 2A for CML cell lines. Importantly,
the ERK5 inhibitor JWG-045, exhibiting lower off-target ef-
fects than XMD8-92 (Williams et al., 2016), suppressed the
progenitor cell potential of primary CML cells (Figure 4A,
no. 34). CRA was also markedly inhibited or suppressed by
BIX02189 (nos. 26, 29, and 34), but largely insensitive to
imatinib (nos. 18, 26, 29, and 34) or dasatinib (nos. 26
and 29), in agreement with the well-known insensitivity
of LSCs to TKi (Graham et al., 2002; Giuntoli et al., 2006,
2011; Cheloni et al., 2017; Hu et al., 2006; Corbin et al.,
2011). Of relevance in view of a possible translational use
of these drugs, 10 mMXMD8-92 or BIX02189 did not affect
the CRA of normal CD34+ PBMCs (Figure 4B). Thus, the
highest concentration tested (10 mM)of either drug, despitemeans ± SD of data normalized for the respective vehicle-treated contr
S4C and S4D for data of single experiments); *p% 0.05; ***p% 0.0
(F and G) Effects of MEK5/ERK5 inhibitors on the differentiation poten
shown in (E), differential CFA was scored for primary CML (F) or norma
the respective vehicle-treated control. *p% 0.05; **p% 0.01; ***p%
not indicated.
(H) Effects of MEK5/ERK5 inhibitors on primary CD11b+ CML cells. Pati
(Vehicle), 10 mM XMD8-92 (XMD), 10 mM BIX02189 (BIX), or 1 mM imat
cells were measured by flow cytometry. Data are means ± SD of data
6 Stem Cell Reports j Vol. 11 j 1–15 j October 9, 2018its effectiveness onnormal CD34+ PBMCs in a colony assay
(CFA, Figure 3E), was ineffective in a short-term repopula-
tion ability assay (CRA, Figure 4B), pointing to a specific
role of ERK5 in the maintenance of CML, but not normal,
progenitor cell potential. The effects of pharmacological in-
hibition of the ERK5 pathway on this potential of primary
CML cells were then confirmed by serial CFA assay. Both
XMD8-92 andBIX02189 suppressedCFAupon serial replat-
ing of total (Figure 4C) or CD34+ (Figure 4D) BMMCs from
CMLpatients.MEK5/ERK5 inhibitors strongly reducedCFA
starting from the primary cultures and throughout subse-
quent passages. Imatinib, on the contrary, exhibited partial
(nos. 27 and 25) or no (nos. 28 and35) effects onCFAof sec-
ondary and tertiary cultures. Imatinib exhibited indeed a
fading-off effect while progressing with passages, showing
a paradoxical stimulatory effect in the case of patient no.
35. This is inkeepingwith thenotion that imatinib gets pro-
gressively less effective with the increase of the hierarchical
level of progenitor. We then tested the effects of MEK5/
ERK5 inhibitors on a longer-term repopulation ability
than that detectable by CRA assays (Ploemacher, 1997;
Eaves, 2015), using the long-term culture-initiating cell
(LTC-IC) assay. We confirmed the marked efficacy of these
inhibitors, but not imatinib, in reducing the stem cell po-
tential of primary CML cells but not that of normal PBMCs
(Figure 4E). Finally, MEK5/ERK5 inhibitors, but not imati-
nib, strikingly reduced the percentage of CML BMMCs ex-
pressing CD26, a specific LSC marker in CML (Herrmann
et al., 2014;Culenet al., 2016) (Figure4F). In conclusion,us-
ing several different in vitro assays, we showed that ERK5
pathway inhibitors were capable to target progenitor and
stem CML cells.
Imatinib Does Not Impair the Effects of XMD8-92 in
Reducing CML Cell Growth and Progenitor Cell
Potential
In view of a possible therapeutic use of ERK5 pathway in-
hibitors, it was necessary to evaluate if XMD8-92 main-
tained the capacity to suppress CML progenitor cell poten-
tial when combined with the standard TKi treatment
(Figure 5). The XMD8-92/imatinib combination in low
oxygen for 7 days was more effective than either drug
alone in reducing the number of viable KCL22 and K562ol. The number of patients/healthy donors is indicated (see Figures
01; ns, not significant.
tial of primary CML or normal CD34+ cells. In the same experiments
l (G) CD34+ cells. CFE values are means ± SEM of data normalized for
0.001; to reduce figure cluttering, non-significant differences are
ent-derived cells were incubated in normoxia and treated with DMSO
inib (IM) from time 0 to day 3. The percentages of CD11b-expressing
from three patients; ***p < 0.001 versus time 0 (t0).
CFigure 4. Effects of Pharmacological Inhibition of the ERK5 Pathway on the Stem Cell Potential of Primary CML Cells
(A and B) Effects of MEK5/ERK5 inhibitors on CRA of primary CML and normal CD34+ cells. Kinetics of repopulation of drug-free normoxic
LC2 established with CML BMMCs (A) or normal CD34+ PBMCs (B) that had been previously incubated in 0.1% O2 for 7 days in LC1 while left
untreated or treated with DMSO (Vehicle) or the indicated inhibitors. Data represent results from single experiments (no. 24; no. 26, Exp1:
means ± SD from triplicates). BC, blast crisis; CP, chronic phase.
(C and D) Effects of MEK5/ERK5 inhibitors on serial CFA of primary CML cells. Total (C) or CD34+ (D) BMMCs from CML patients were treated
with DMSO (Vehicle) or the indicated inhibitors from time 0 of incubation in passage I culture. Cells were washed to remove drugs and
replated weekly (II–III) and colonies scored on day 7 after each passage. Values are means ± SD of data, normalized for the respective
vehicle-treated control, from single experiments performed in duplicate; *p% 0.05; **p% 0.01; ***p% 0.001; ns, not significant; CP,
chronic phase.
(legend continued on next page)
Stem Cell Reports j Vol. 11 j 1–15 j October 9, 2018 7
Please cite this article in press as: Tusa et al., Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic
Myeloid Leukemia Stem Cells, Stem Cell Reports (2018), https://doi.org/10.1016/j.stemcr.2018.08.016
Please cite this article in press as: Tusa et al., Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic
Myeloid Leukemia Stem Cells, Stem Cell Reports (2018), https://doi.org/10.1016/j.stemcr.2018.08.016cells in culture (Figure 5A). More importantly, XMD8-92
completely suppressed progenitor cell potential, regardless
of the presence or the absence of imatinib in LC1 (Fig-
ure 5B). Identical results were obtained using primary
CML cells (Figure 5C).The Combination of ERK5 Pathway Inhibitors with
Imatinib Decreases the Expression of Stem Cell-
Related Proteins
We then determined the effects of ERK5 pathway inhibitors
on the expression of p21 and p27, two ERK5-regulated pro-
teins (Rovida et al., 2008, 2015; Tusa et al., 2018; Perez-
Madrigal et al., 2012) that are known to regulate the normal
and neoplastic HSC compartments (Viale et al., 2009;
Cheng et al., 2000a). Following a 7-day incubation in low
oxygen, ERK5 inhibition resulted in p27 upregulation
(Figure 6A), similarly to that observed at day 3 (Figure 1E).
Imatinib administration determined similar effects, as re-
ported previously (Grimmler et al., 2007). On the other
hand, p21 expression was not increased upon ERK5 inhibi-
tion, indicating that p21 is not regulated by ERK5 in CML
cells under these experimental conditions. The combina-
tion of XMD8-92 with imatinib suppressed both p27 and
p21 proteins. This combination also decreased the expres-
sion of the stemness-related genes c-MYC, SOX2, and
NANOG (Laurenti et al., 2008; Stivarou et al., 2015), but
not that of OCT3/4 and KLF4, in comparison with either
treatment alone or vehicle (Figure S6 and not shown).
Finally, the combination of XMD8-92 or BIX02189 with
imatinib was significantly more effective than single treat-
ments in reducing the percentages and mean fluorescence
intensity values of cells expressing the CML stem cell
marker CD26 in KCL22 cells incubated in low oxygen for
7 days (Figure 6B). These experiments could not be per-
formed with K562 cells because these cells do not express
CD26 (not shown). On the whole, these results indicated
that combined ERK5 pathway and BCR/ABL inhibition
was more effective than single treatments in reducing the
expression of stem cell-related proteins.DISCUSSION
This study shows that small-molecule inhibitors targeting
the ERK5 pathway almost suppressed progenitor/stem cells(E) Effects of MEK5/ERK5 inhibitors on primary CML and normal LTC-ICs
LC1 treated with DMSO (Vehicle) or the indicated inhibitors and tra
replated and colony number was scored after 14 days. Values are mean
expressed as a fraction of the value obtained for vehicle-treated culture
(F) Effects of MEK5/ERK5 inhibitors on CD26+ CML BMMCs. Cells were
DMSO (Vehicle), 1 mM imatinib (IM), 10 mM XMD8-92 (XMD), or 10 m
expressing cells were determined by flow cytometry. Data are means
8 Stem Cell Reports j Vol. 11 j 1–15 j October 9, 2018within CML patient-derived cells and cell lines. This
conclusion was reached using several functional assays,
including CRA, serial CFA, and LTC-IC, the latter assay be-
ing capable of revealing HSCs of the highest hierarchical
level detectable in vitro (Ploemacher, 1997; Eaves, 2015).
This report identifies ERK5 pathway inhibition as a way
to target LSCs, those of CML in particular.
With respect to the effects of ERK5 pathway inhibition
on the overall cell population of CML lines, we found
that the reduction of the number of viable cells occurred
through a cytostatic rather than cytotoxic effect. The
observed block of cell cycle in G0/G1 phase was similar
to that described for other cell types (Rovida et al., 2015;
Perez-Madrigal et al., 2012; Kato et al., 1998) and can be ex-
plained by the increase of p27 expression (Rovida et al.,
2008, 2015; Perez-Madrigal et al., 2012). The fact that the
ERK5 pathway seems to be necessary for the proliferation
but not survival of CML cells is in keeping with data re-
ported for other cell types (Lin et al., 2016; Lochhead
et al., 2016).
Referring to the overall primary CML cell population,
XMD8-92 or BIX02189 reduced the number of viable cells
incubated in low oxygen as well as CFA. The reduction of
viable cells was, at least in part, due to apoptosis. Although
we did not deepen the mechanisms involved in the trig-
gering of apoptosis upon ERK5 inhibition, it would be
interesting to investigate the possible role of nuclear factor
kB, which has been reported to be inhibited by XMD8-92
and to collaborate in enhancing sensitivity of K562 cells
to imatinib (Wang et al., 2016a). The occurrence ofmeasur-
able apoptosis in primary cells upon ERK5 pathway inhib-
itors seems to exclude an induction of quiescence, which
may be responsible for the inefficacy of TKi on LSCs (Gra-
ham et al., 2002). Furthermore, ERK5/MEK5 inhibition
determined a reduction of viable cell number and CFA of
CML CD34+ cells but not cell viability or at a lower extent
(CFA) of normal CD34+ cells. Noteworthy, different effects
ofMEK5/ERK5 inhibition onCML versus normal cells were
also observed with respect to the suppression of CML pro-
genitor/stem cell potential as determined by CRA or LTC-
IC assays. Along this line, XMD8-92 reduced the number
of leukemic CML cells in vivo, in either PB or BM, with no
effect on non-leukemic cells. Altogether, these data point
to a good potential therapeutic index of ERK5 pathway in-
hibitors on the more immature CML cell subsets.. CML BMMCs or normal PBMCs were incubated in 0.1% O2 for 48 hr in
nsferred to drug-free normoxic LC2. After 5 weeks, LC2 cells were
s ± SD of data from one experiment performed in duplicate and are
. **p% 0.01; ***p% 0.001; ns, not significant; CP, chronic phase.
incubated in normoxia for 3 days and left untreated or treated with
M BIX02189 (BIX) from time 0. The percentages of CD26+/CD34+-
± SD of data from three patients; **p% 0.01 versus vehicle.
AB
C
Figure 5. Effects of the XMD8-92/Imatinib
Combination on CML Cell Lines and Primary
Cells
(A) Effects of XMD8-92/imatinib combination
on the number of viable CML cells. KCL22 or
K562 cells were incubated in 0.1% O2 and
treated with DMSO (Vehicle), XMD8-92
(10 mM), imatinib (1 mM), or their combina-
tion (XMD + IM) from time 0 and viable cells
counted at the indicated times. Values are
means ± SD of data from three independent
experiments; *p < 0.05; **p < 0.01; ***p <
0.001.
(B and C) Effects of XMD8-92 alone or in
combination with imatinib on CRA of CML
cells. Repopulation of drug-free normoxic LC2
by KCL22 or K562 (B) or patient-derived (C)
CML cells that had been previously incubated
in 0.1% O2 for 7 days in LC1 treated as in
(A). Values are means ± SD of data from
three independent experiments (B) or from
single experiments (C). CP, chronic phase. (B)
Differences between XMD8-92- or imatinib/
XMD8-92-treated cultures were significant
(p % 0.05) from day 5 (versus vehicle-
treated) or day 7 (versus imatinib-treated) on
(KCL22). Differences between XMD8-92 or
imatinib/XMD8-92 with respect to vehicle- or
imatinib-treated cultures were significant
(p% 0.05) from day 14 on (K562).
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ERK5 activity is necessary for themaintenance of CML pro-
genitor and stem cells. This conclusionwas reached first us-
ing CML cell lines, which we previously demonstrated to
comprise cell subsets endowed with progenitor cell poten-
tial (Giuntoli et al., 2006, 2007, 2011). Data were then
confirmed using primary cells derived from a number of
CML patients. To evaluate the effects of drugs on progeni-
tor cell potential, we incubated CML cells in low oxygen,
a condition typical of BM sites where normal HSCs are
selectively maintained (Parmar et al., 2007; Eliasson and
Jonsson, 2010), and CML cell growth but not LSC mainte-nance is reduced (Giuntoli et al., 2006, 2007, 2011). Using
this strategy, it was possible to demonstrate with CML cell
lines and primary cells that XMD8-92 or BIX02189 almost
suppressed progenitor/stem cell potential, as determined
by a number of functional assays, as well as CD34+/
CD26+ cells. Imatinib, by contrast, was largely ineffective,
in keeping with BCR/ABL protein suppression in low oxy-
gen. Our results therefore indicate that ERK5 is necessary
for the maintenance of BCR/ABL-independent/TKi-insen-
sitive LSCs.
The overlapping results obtained using the ERK5
inhibitor XMD8-92 or the MEK5 inhibitor BIX02189Stem Cell Reports j Vol. 11 j 1–15 j October 9, 2018 9
A B
Figure 6. Effects of the Combination of MEK5/ERK5 Inhibitors with Imatinib on the Expression of Stem Cell-Related Proteins
(A) Cells were incubated in 0.1% O2 and treated with DMSO, 1 mM imatinib, 10 mM XMD8-92 (XMD), or their combination from time 0 to day
7. Cells were then lysed and immunoblotting performed; tubulin is a loading control; representative images from three independent
experiments.
(B) KCL22 cells were incubated in 0.1% O2 and treated with DMSO (Vehicle), 10 mM XMD8-92 (XMD), 10 mM BIX02189 (BIX), 1 mM imatinib
(IM), or their combination (XMD + IM; BIX + IM) for 7 days. Percentages of CD26+ cells were measured by flow cytometry. Dot plots from one
representative experiment including means ± SD (left) and histograms relative to CD26 mean fluorescence intensity values from three
independent experiments (mean ± SD, right) are shown; *p < 0.05; **p < 0.01; ***p < 0.001.
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the MEK5-ERK5 axis in CML. Furthermore, this seems to
indicate thatMEK5 is themain ERK5 activator in CML cells
and alternative ERK5 activators are unlikely involved (Dı´az-
Rodrı´guez and Pandiella, 2010; Honda et al., 2015). Finally,
a direct involvement of ERK5 in the maintenance of CML
progenitor cell potential was confirmed in K562 cells using
ERK5-specific shRNA. The involvement of ERK5 pathway
in stem cell biology has been recently reported for embry-
onic and mesenchymal stem cells (Williams et al., 2016;
Lai et al., 2012;Wang et al., 2016b). Our work nowprovides
a link between ERK5 pathway and LSC maintenance.
Another important outcome of this study is that the com-
bination of MEK5 or ERK5 inhibitors with TKi emerged as a
treatment of high potential therapeutic value. Indeed, the
combination XMD8-92/imatinib was more effective than
either drug alone in the debulking of CML cell lines. These
results are in keeping with a previous report showing that
ERK5 expression and activity are partially BCR/ABL-depen-
dent and that the combination of imatinib treatment with
ERK5 genetic suppression was more effective than imatinib
alone in reducing the survival of CML cell lines (Buschbeck
et al., 2005). Our results further support that ERK5 signaling
is either dependent on or independent of BCR/ABL. More
importantly, the combination with imatinib did not inter-
fere with the suppressive effect of XMD8-92 on progenitor
cell potential in CML cell lines and primary CML cells.
Rather, this combination may provide advantages, as the
XMD8-92/imatinib combination, differently from the sin-
gle treatments, reduced the expression of stemness-related
genes such as c-MYC, SOX2, and NANOG (Li et al., 1999;
Laurenti et al., 2008; Stivarou et al., 2015), and suppressed10 Stem Cell Reports j Vol. 11 j 1–15 j October 9, 2018both p21 and p27 proteins.With respect to the latter effects,
p21 is critical for preventing HSC and LSC exhaustionwhile
p27 regulates the proliferation and pool size of hematopoi-
etic progenitor cells (Cheng et al., 2000b).We thereforemay
speculate that, in the absence of both p21 and p27, the stem
and progenitor cell compartments would be exhausted
following drug-induced stress. Furthermore, while the
involvement of p21 in ERK5-mediated regulation of the
stem cell compartment seems to be excluded, the observed
increase of p27 protein upon ERK5 pathway inhibitionmay
prevent LSC self-renewal, as proposed for normal HSCs, and
therefore reduce the size of the CML stem cell compartment
(Wilson and Trumpp, 2006). The combined ERK5 pathway
and BCR/ABL inhibition was also capable to target imati-
nib-insensitive cells expressing CD26, an LSC marker in
CML (Herrmann et al., 2014; Culen et al., 2016). Taken
together, the above results pointed to an excellent comple-
mentarity of TKi with ERK5 pathway inhibitors in view of a
possible therapeutic use of the latter.
In conclusion, ERK5 pathway inhibition appeared
capable to target CML progenitor and stem cells as well
as, especially in combination with TKi, the overall CML
cell population, thus representing a promising strategy to
prevent relapse of the disease and to contribute to TKi-
driven induction of remission.EXPERIMENTAL PROCEDURES
Cells and Culture Conditions
KCL22, K562, and LAMA-84 (Kubonishi andMiyoshi, 1983; Lozzio
and Lozzio, 1975; Blom et al., 1996) BCR/ABL-positive CML cell
lines were cultured in RPMI 1640 medium supplemented with
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50 U/mL penicillin, and 50 mg/mL streptomycin (all from Euro-
Clone, Paignton, UK) and incubated at 37C in a water-saturated
atmosphere containing 95% air (21% O2) and 5% CO2 (referred
to as ‘‘normoxia’’). Cell lines were routinely tested for mycoplasma
contamination and BCR/ABL expression and yearly profiled
(Promega PowerPlex Fusion System kit; BMR Genomics, Padova,
Italy). Cultures were renewed every 2 to 3 months by thawing a
new batch of cells.
Patient-derived CML cells (see Table 1 for patient characteristics)
andhealthy donor cells were collected following informed consent
and under approval of the Ethical Committee of AOUC (authoriza-
tion no. 520/10, October 18, 2010, renewed with no. 2015/
0032965, November 4, 2015). MCs from BM of CML patients or
PB of healthy donors were isolated by Ficoll-Hypaque gradient
(Cedarlane Laboratories, ON, Canada). CML BMMCs and normal
PBMCs were cultured in IMDM supplemented with 20% FBS,
2 mM glutamine, 50 U/mL penicillin, 50 mg/mL streptomycin,
and, in LC1, 50 ng/mL Flt-3 ligand (no. 300-19), 20 ng/mL TPo
(no. 300-18), 50 ng/mL stem cell factor (SCF) (no. 300-07),
10 ng/mL interleukin-3 (IL-3) (no. 200-03), or, in LC2, 50 ng/mL
SCF, 100 ng/mL G-CSF (no. 300-23), 20 ng/mL IL-6 (no. 200-06),
and 10 ng/mL IL-3 (PeproTech, Rocky Hill, NJ, USA). CD34+ cells
were obtained from Ficoll-isolated BMMCs or PBMCs using
CD34 MicroBead Kit (no. 130-046-703, MACS, Miltenyi Biotec,
Bergisch Gladbach, Germany) following the manufacturer’s
protocol. CD34+ enrichment was verified by flow cytometry.
Experiments were performed with exponentially growing cells
(3 3 105/mL) incubated in normoxia or 95% N2, 5% CO2, and
0.1% O2 (low oxygen) in a DG250 Anaerobic Workstation (Don
Whitley Scientific, Shipley, Bridgend, UK).Drugs
ERK5 inhibitors XMD8-92 (Yang et al., 2010) and JWG-045
(Williams et al., 2016) (Gray’s laboratory and MedChemexpress
LLC, Princeton, NJ, USA); MEK5 inhibitor BIX02189 (Tatake et al.,
2008) (MedChemexpress LLC); imatinib (no. 202180, Santa Cruz,
Biotechnology, Dallas, TX, USA); dasatinib (no. 1586, Biovision,
Milpitas, CA, USA). All drugs were dissolved in DMSO.Kinase Assay
Kinase activity of endogenous ERK5 was measured using a non-
radioactive ERK Assay Kit (no. 17–191, Merck Millipore, Billerica,
MA, USA) following the manufacturer’s instructions. The ability
of immunoprecipitated ERK5 to phosphorylate myelin basic pro-
tein was evaluated by western blotting.Measurement of Cell Viability, Apoptosis, and Cell-
Cycle Phases
Cell viability was measured by trypan blue exclusion test and
IC50 values were calculated using GraphPad Prism software (La
Jolla, CA, USA). Apoptosis (Annexin-V-FLUOS Staining Kit, no.
11988549001, Roche Diagnostics, Basel, Switzerland) and cell-cy-
cle phase distribution (propidium iodide staining) were estimated
by flow cytometry using a FACSCanto (Beckton Dickinson, San
Jose`, CA, USA) as reported previously (Rovida et al., 2015).CRA Assay
The CRA assay is an in vitro substitute for the MRA assay in vivo
where the estimate of the overall progenitor cell potential (short-
term repopulation ability) is obtained via cell transfer to liquid cul-
tures (LC2) tomonitor the entity and kinetics of their repopulation
(Giuntoli et al., 2006, 2007; Ivanovic et al., 2002; Cipolleschi et al.,
2000, 2013). Cells (3 3 105 cells/mL) were incubated for 7 days in
low oxygen (LC1) while being subjected to drug treatment (a full
dose at time 0 and a half dose on day 3). Cells were then washed
free of drug and transferred (3 3 104 cells/mL) to normoxic LC2,
where kinetics of viable cell number was measured, reflecting the
CRA of LC1 cells. Culture medium was never changed during
LC1 or LC2.
LTC-IC Assay
BMMCs fromCMLpatients or normalCD34+PBMCs (13 106/mL)
were drug-treated for 48 hr in low oxygen, resuspended in Myelo-
cult (no. 05100, Stem Cell Technology, Vancouver, BC, Canada)
supplemented with hydrocortisone (106 M), seeded (BMMCs
from CML patients 2 3 106/35-mm dish; normal CD34+ PBMC
5 3 103/35-mm dish) onto a feeder layer of irradiated (8,000
cGy) murine stromal cells (M2-10B4 cell line) and incubated in
normoxia. Half medium was replaced weekly. After 5 weeks, cells
were recovered, counted, and replated (5 3 104 cells/35-mm
dish) in methylcellulose-containing medium (no. 04435, Stem
Cell Technology) (Sutherland et al., 1989). Colonies were scored
after 14 days of incubation.
CFA Assay
CFA and serial CFA were performed as recently reported (Cheloni
et al., 2017). Number and type of colonies were scored after
7 days. When serial CFA assay was performed, colony cells recov-
ered from day 7 cultures were washed to remove drugs, replated
(1 3 105/35-mm dish) in methylcellulose-containing medium
and incubated for 7 days. Colony formation efficiency was calcu-
lated dividing the number of colonies scored by the number of
plated cells.
Cell Lysis and Western Blotting
Total cell lysates and western blotting were performed as
described previously (Rovida et al., 2008). Antibodies used are
listed in Table S1.
RNA Interference by Lentiviral Vectors
Stable knockdown of ERK5 in K562 cells was performed using
lentiviral vectors carrying shRNA specific for ERK5 (Table S2), as
described previously (Rovida et al., 2015).
Mice
C57BL/6J-CD45.1 mice (The Jackson Laboratory, Bar Harbor, ME,
USA) were handled in accordance with protocols and regulations
approved by the IACUC of University of Massachusetts Medical
School. CML mice were treated twice daily with XMD8-92
(50 mg/kg) or placebo (30% 2-hydroxypropyl-b-cyclodextrin), via
intraperitoneal injection, for 7 days starting from day 7 after BM
transplantation.Stem Cell Reports j Vol. 11 j 1–15 j October 9, 2018 11
Table 1. Patients’ Characteristics
Patient ID Age at Diagnosis CML Phase Sokal Risk BCR/ABL Transcript ELN Criteria Response
4 45 BC NA ND non-respondera
5 61 CPb high b3a2 (p210) optimal response to Dasa
9 59 ECP low b3a2 (p210) optimal response to IM
10 46 LCP low b3a2 (p210) failure to IM, Dasa, Nilc
16 28 ECP low b2a3 (p210) optimal response to IM
17 54 ECP low b2a2 (p210) optimal response to Nil
18 66 ECP intermediate ND optimal response to Dasa
24 61 LCP intermediate b3a2 (p210)
e1a2 (p190)
optimal response to IM
25 29 LCP intermediate b3a2 (p210) failure to Bos; response to Dasac
26 57 ECP intermediate b2a2 (p210)
e1a2 (p190)
optimal response to IM
28 66 ECP low b2a2 (p210) optimal response to IM
29 78 LCP low ND sub-optimal response to IM
32 40 ECP low b3a2 (p210)
b2a2 (p210)
optimal response to Dasa
34 47 ECP intermediate ND sub-optimal response to Nil
35 60 ECP low b2a2 (p210) optimal response to Dasa
36 55 ECP intermediate b3a2 (p210) optimal response to Nil
37 60 ECP intermediate b3a2 (p210) optimal response to IM
38 74 ECP intermediate b3a2 (p210) optimal response to IM
39 69 ECP intermediate b3a2 (p210) optimal response to Dasa
40 72 ECP intermediate b3a2 (p210) NA (too short therapy follow up)
41 42 ECP intermediate b3a2 (p210) NA (too short therapy follow up)
42 60 ECP intermediate b3a2 (p210) NA (too short therapy follow up)
43 51 ECP low b3a2 (p210) NA (too short therapy follow up)
45 77 ECP intermediate b3a2 (p210) NA (too short therapy follow up)
46 75 ECP low b3a2 (p210) optimal response to IM
ECP, early chronic phase (CP); LCP, late CP; BC, blast crisis; ELN, European Leukemia Net (2013); Bos, bosutinib; Dasa, dasatinib; IM, imatinib; Nil, nilotinib;
NA, not applicable; ND, not done.
aAs expected on the basis of diagnosis (BC).
bRelapse post allogeneic transplant.
cBCR/ABL mutations not found.
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Retroviruses were prepared and CML induced in mice as described
previously (Cheloni et al., 2017; Li et al., 1999; Peng and Li, 2010).
Donor mice were injected with 5-FU (200mg/kg; no. 6627, Sigma-
Aldrich) via tail vein and sacrificed after 4 days. BM cells were
flushed out of femurs and tibiae, infected with the above viruses,
counted and transplanted (5 3 105 cells in 300 mL/mouse) into12 Stem Cell Reports j Vol. 11 j 1–15 j October 9, 2018recipient mice pre-treated with two doses of 550 cGy gamma
2 hr apart from each other.
Flow Cytometry
Intact or permeabilized (0.5% Tween 20) cells were incubated with
primary (Table S1) and then fluorescence in situ hybridization-
or allophycocyanin-conjugated secondary antibodies (Chemicon
Please cite this article in press as: Tusa et al., Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic
Myeloid Leukemia Stem Cells, Stem Cell Reports (2018), https://doi.org/10.1016/j.stemcr.2018.08.016International, Temecula, CA, USA). Background signal was deter-
mined using matched isotype control. 7AAD (no. 559925, BD
Biosciences, San Jose`, CA, USA)-negative cells were considered
for analysis.
Statistical Analysis
Data represent means ± SEM or ± SD of values obtained in at least
three independent experiments; p values were calculated using
Student’s t test or one-way ANOVA (when more than two samples
were compared).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and two tables and
can be found with this article online at https://doi.org/10.1016/j.
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. A, B) Pharmacological inhibition of ERK5 activity. KCL22 or K562 cells 
were treated with DMSO (Vehicle), 10 µM XMD8-92 or 10 µM BIX02189 for the indicated times 
and lysed. Immunoprecipitated ERK5 was subjected to nonradioactive in vitro kinase assay. The 
drugs impaired ERK5 ability to phosphorylate its substrate myelin basic protein (MBP). Migration 
of molecular weight markers is indicated (kDa). C-E) Determination of XMD8-92 and BIX02189 
IC50. Dose-response curves of XMD8-92 (C) and BIX02189 (D) in KCL22 or K562 cells after 72 
hours of treatment or DMSO (CTR) in 21% O2. Values are means ± SD of data from three 
independent experiments normalized to matched vehicle-treated sample. (E) IC50 values for XMD8-
92 and BIX02189 in CML cells treated for 72 hours in 21% or 0.1% O2. Values represent means ± 
SD of data from three independent experiments. F) Effects of MEK5/ERK5 inhibitors on KCL22 and 
K562 cell number in 21% O2. Cells were treated with DMSO (Vehicle) or inhibitors at the indicated 
concentrations from time 0 and viable cells were counted on day 3. Values represent means ± SD of 
data from three independent experiments; *p < 0.05; **p < 0.01. G, H) Effects of XMD8-92 on the 
number of viable ERK5-silenced CML cells. (G) Parental or transduced K562 cells with non-targeting 
control (shNT) or one ERK5-targeting shRNA (shERK5-2) and left untreated (Unt) or treated with 
DMSO (Veh) or XMD8-92 at the indicated concentration from time 0 and viable cells were counted 
on day 3. Values are means ± SD of three independent experiments. *p ≤ 0.05; ***p ≤ 0.001; ns, not 
significant. (H) Immuno-blotting from total cell lysates of parental or transduced K562 cells with 
shNT or shERK5-2. Tubulin is loading control. Migration of molecular weight markers is indicated 
(kDa). 
 
Supplementary Figure 2. Effects of MEK5/ERK5 inhibitors on KCL22 and K562 apoptosis and 
cycle phase distribution.  A-D) Cells were incubated in 0.1% (A, B) or 21% O2 (C, D) and treated 
with DMSO (Vehicle) or inhibitors at the indicated concentrations from time 0. The percentages of 
cells in early or late apoptosis were measured by Annexin V test and flow cytometry on day 3 of 
incubation. Values represent means ± SD of data from three independent experiments; *p < 0.05, **p 
< 0.01 versus vehicle. E, F) Cell cycle phase distribution obtained from cells treated as C and D; data 
from three independent experiments are shown (means ± SEM) in the Table; *, p ≤ 0.05 versus 
vehicle. G) Immuno-blotting of total lysates of cells treated as in C and D; GAPDH is a loading 
control; migration of molecular weight markers (kDa) is indicated; representative images from four 
independent experiments are shown. 
 
Supplementary Figure 3. A) Effects of incubation in 0.1% O2 on the expression of ERK5 protein in 
CML cell lines. KCL22 or K562 cells were incubated in 0.1% O2 for indicated times. Immuno-
blotting from total cell lysates was then performed. Tubulin is a loading control. Migration of 
molecular weight markers is indicated (kDa). B) Effects of imatinib on the expression of ERK5 protein 
in CML cell lines in low oxygen. KCL22 or K562 cells were incubated in 0.1% O2 and treated with 
DMSO (Vehicle) or 1 µM imatinib from time 0 to day 3. Immuno-blotting from total cell lysates was 
then performed. Tubulin is a loading control. Migration of molecular weight markers is indicated 
(kDa). 
 
Supplementary Figure 4. A) Effects of MEK5/ERK5 inhibitors on the number of viable primary 
CML cells. BMMC explanted from 11 CML patients were incubated at 0.1% O2 in cultures treated 
with DMSO (Vehicle) or the indicated inhibitors and viable cells were counted at day 3. (A) Values 
are data from single experiments (performed in duplicate when error bars, indicating SD, are present) 
normalized for the respective vehicle-treated control. These data are averaged in Figure 3A. B) Effects 
of XMD8-92 on leukemic PB WBC in vivo. CML mice (mice/group: n=6) were treated twice daily 
with XMD8-92 (50 mg/Kg) or placebo and euthanized after 1 additional day. The number of GFP+ 
(leukemic) PB myeloid (Gr-1+) cells are shown as means ± SD. *, p < 0.05. C, D) Effects of XMD8-
92 on CFA of primary CML or normal CD34+ cells. CD34+-enriched BMMC from CML patients 
(C) or CD34+-enriched PBMC from healthy donors (D) were plated in methylcellulose containing 
medium and treated with DMSO (Vehicle) or inhibitors at the indicated concentrations from time 0 
and the number of colonies was scored after 7 days. CFE values are means ± SD of data from single 
experiments performed in duplicate; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ns, not significant.  
 
Supplementary Figure 5. Effects of the pharmacological inhibition of ERK5 on the expression 
of stem cell markers. KCL22 or K562 cells were incubated in 0.1% O2 and treated with DMSO 
(Vehicle) or the combination (XMD + IM) of XMD8-92 (10 µM) and imatinib (1 µM) for 7 days and 
the expression of stem cell markers was then measured by flow cytometry. Values are means ± SD 
of mean fluorescence intensity (MFI) data obtained from four independent experiments; *, p < 0.05; 
**, p < 0.01.  
 
 
 
Supplementary Table 1. Specification of antibodies used in the experiments. 
Protein Use Source Notes Cat. No. Company 
pABL-Y245 WB rabbit polyclonal  #2862 Cell Signaling Technology, Danvers, MA, USA 
c-ABL WB rabbit polyclonal  #2861 Cell Signaling Technology, Danvers, MA, USA 
pERK5-T218/Y220 WB rabbit polyclonal  #3371 Cell Signaling Technology, Danvers, MA, USA 
ERK5 WB rabbit polyclonal  #3372 Cell Signaling Technology, Danvers, MA, USA 
ERK5 IP rabbit polyclonal C-20 c-1284 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
p27Kip1 WB rabbit polyclonal  #2552 Cell Signaling Technology, Danvers, MA, USA 
pCRKL-Y207 WB rabbit polyclonal  #3181 Cell Signaling Technology, Danvers, MA, USA 
VINCULIN WB mouse monoclonal  V9131 Sigma-Aldrich St. Louis, MO, USA 
GAPDH WB goat polyclonal V-18 sc-20357 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
TUBULIN WB mouse monoclonal  sc-32293 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
OCT3/4 FC mouse monoclonal C-10 sc-5279 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
KLF4 FC mouse monoclonal  #09-0021 Stemgent, San Diego, CA, USA 
c-MYC FC rabbit polyclonal  #9402 Cell Signaling Technology, Danvers, MA, USA 
SOX2 FC rabbit monoclonal  #3579 Cell Signaling Technology, Danvers, MA, USA 
NANOG FC rabbit monoclonal  #4903 Cell Signaling Technology, Danvers, MA, USA 
CD26-PE FC mouse monoclonal 2A6 #12-0269 Affymetrix eBioscience, San Diego, CA, USA 
pMBP WB mouse monoclonal P12 #05-429 Merck Millipore, Billerica, MA, USA 
CD34-FITC FC  mouse monoclonal 4H11[APG] #21270343 Immuno Tools, Friesoythe, Germany 
WB, western blotting; FC, flow cytometry. 
Supplementary Table 2. Lentiviral shRNA sequences used in gene knockdown. 
Clone number Region Sequence 
control vector 
TRC1.5-pLKO.1 none 
5’-CCGGCAACAAGATGAAGAGCACCAACTC 
GAGTTGGTGCTCTTCATCTTGTTGTTTTT-3’ 
TRCN0000010271 ERK5 CDS 5’CCGGCCAGTCCAACCTACCAGTCCTCTCG AGAGGACTGGTAGGTTGGACTGGTTTTT-3’ 
TRCN0000010275 ERK5 CDS 5’-CCGGGCCAAGTACCATGATCCTGATCTCG AGATCAGGATCATGGTACTTGGCTTTTT-3’ 
CDS, coding sequence. 
 
 
